Investigational drug · Phase 2
OBX-115
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Tumor Skin, Metastatic Melanoma, Melanoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "OBX-115"
First trial start
2023
Oct 25, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "OBX-115", any sponsor or status.
Conditions studied
As listed on its trial records.
- Tumor Skin
- Metastatic Melanoma
- Melanoma
- Lung Cancer
- Metastatic Lung Cancer
- Non Small Cell Lung Cancer
- Metastatic Non Small Cell Lung Cancer
Approved drugs for the same conditions: Small cell lung cancer · Melanoma · Oncology · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "OBX-115" as an intervention, largest first.
Obsidian Therapeutics, Inc.Industry
NCT06060613 · 254 participants (planned) · Start Oct 25, 2023 · Primary completion Jun 30, 2029
Drug: OBX-115 · For: Tumor Skin; Metastatic Melanoma; Melanoma and 4 more
Sites: Tucson, Arizona; Los Angeles, California; Stanford, California · 14 sites in all
- Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic MelanomaActive, not recruiting
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT05470283 · 21 participants · Start Sep 7, 2022 · Primary completion Apr 1, 2027
Drug: OBX-115; Acetazolamide and 4 more · For: Tumor; Metastatic Melanoma; Melanoma
Sites: Houston, Texas
Newest research
PubMed records naming it or its code names, newest first.
- Regulatable membrane-bound IL-15 engineered TIL cell therapy for immune checkpoint inhibitor-resistant advanced melanoma: pooled analysis of phase 1 and 1/2 trials.
Amaria RN, Chesney JA, Betof AS, et al. · Nat Med 2026
- Top advances of the year in autologous cellular therapy in melanoma and solid tumors.
Loo K, Betof AS · Cancer 2026
- Recent Advances in Tumor-Infiltrating Lymphocyte Therapy for Melanoma.
Zeng H, Mei W, Zeng C · Curr Treat Options Oncol 2026
- Evolving therapeutic pipeline for tumor-infiltrating lymphocytes in metastatic melanoma - a review.
Wu JF, Abid MA, Singh SP, et al. · Front Immunol 2026
- Novel tumor-infiltrating lymphocytes therapy in solid tumors: latest updates from 2025 ASCO annual meeting.
Ma Y, Su X, Feng H · Exp Hematol Oncol 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.